Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Fulvestrant + Pyrotinib in HR+/HER2-low Advanced Breast Cancer
NCT05806671Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2023
- Primary completion
- Jan 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib, pyrotinib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start May 2023; status: not yet recruiting.
02
Drugs
dalpiciclibpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05806671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806671.